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AbstrAct
Introduction Central line-associated bloodstream 
infections (CLABSI) are the most important cause of 
morbidity and mortality in critically ill patients. Evidence-
based interventions when used in form of a bundle have 
proven to decrease CLABSI. Our unit has a high CLABSI 
rate (9/1000 central line days). Therefore, we intend to 
introduce evidence-based CLABSI prevention package in 
our practice to improve CLABSI rates in our NICU within 
limited resources.
Methods and analysis The study will be conducted 
using preanalysis and postanalysis design from January 
2016 to December 2017. It is going to be conducted in 
three phases with phase I being the preimplimentation 
phase where retrospective data will be collected. Phase 
II, implementation phase, where the CLABSI prevention 
package will be introduced and phase III will be follow-up 
to see the impact. Primary outcome will be reduction in 
CLABSI rates.
Analysis plan and reporting For all three phases, 
descriptive analysis will be performed. Nominal data will 
be presented as mean±SD, whereas categorical data will 
be presented as frequencies and percentages. To compare 
the effect of intervention we will use independent sample 
t-test for continuous outcomes, whereas Χ2 test will be 
used for categorical outcomes. Relative risk ratios, 95% CI, 
and p values will be determined. Incidence density will 
be calculated and Poisson regression will be used to 
determine factors associated with incidence of CLABSI. 
Microbiological profiles and antimicrobial resistance 
pattern will be reported as pan sensitive, multidrug-
resistant organism and carbapenem-resistant organism. 
SQUIRE V.2.0 guidelines will be used for manuscript writing 
and reporting.
IntroductIon
Healthcare-associated infections (HAI) are 
a major problem worldwide.1Among HAI, 
central line-associated bloodstream infec-
tions (CLABSI) are the most important 
cause of morbidity, mortality and prolonged 
hospital stay, especially in critically ill 
patients.2 Risk of neurodevelopmental 
impairment significantly increases with one 
or more episodes of HAI in very low birth-
weight infants.3 Although a 46% decrease in 
CLABSI has occurred in hospitals across the 
USA from 2008 to 2013, an estimated 30 100 
CLABSI still occur in intensive care units 
(ICU) and wards of the USA.4 Due to many 
factors in low-resource countries, CLABSI 
are either unaddressed or under-reported, 
meaning that the impact of CLABSI-re-
lated mortality and morbidity may be much 
higher than what is reported. In a review 
of literature, neonatal intensive care unit 
(NICU) CLABSI rates ranged from 2.6 to 60 
cases per 1000 central line days in limited-re-
source countries in comparison with 2.9 
cases per 1000 central line days in the USA.5 
What this study hopes to achieve?
 ► If successful this can be used at a larger scale for 
CLABSI prevention both within our institution and 
other facilities worldwide.
 ► It might be helpful to understand the spectrum of 
microorganisms and their antimicrobial resistance.
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Protocol
What is already known about this subject?
 ► CLABSI is defined as a LCBI (Laboratory confirmed 
blood stream infection) where central line was in 
place for greater than two calendar days on the 
date of the event, with day of device placement 
being day one, and the line was also in place on the 
date of the event or the day before.
 ► In developing countries CLABSI is either un 
addressed or under reported
 ► Interventions for reduction of CLABSI when used in 
form of bundles have proven to be efficacious.
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Since Pronovost et al landmark paper in 2006 indi-
cating the usefulness of central line insertion bundles 
in reducing CLABSI,6 significant amount of research 
has led to implementation of line insertion and mainte-
nance bundles in ICU worldwide leading to significant 
reduction in CLABSI rates. A recent systemic review 
and meta-analysis showed a risk reduction in CLABSI 
incidence from 6.4 per 1000 catheter days to 2.5 per 
1000 catheter days after implementation of these 
bundles. Significantly higher risk reduction were also 
noted in studies having baseline incidence rates of 5 per 
1000 catheter days or greater.7 A healthcare bundle is 
defined as a small, straightforward set of evidence-based 
practices that, when performed collectively and reli-
ably, have been proven to improve patient outcomes.8 
Merging several evidence-based catheter care practices 
into one system increases chances of its adherence and 
eventual success.
Our unit at the Aga Khan University Hospital (AKUH) 
is a leading tertiary care private sector teaching hospital 
located in Karachi, Pakistan with a 24-bedded level 3 
NICU. We have four bays of five cots each along with 
four isolation rooms. We admit approximately 800–1000 
patients per year including those born at AKUH and its 
affiliated hospitals along with those who are transferred 
from outside hospitals. Our nurse-to-patient ratio is 
usually 1:2 for non-infected patients and 1:1 for culture 
proven infections. Our hospital has an infection control 
team which comprises trained infection control nurses 
and an infectious disease physician. These, along with a 
dedicated neonatologist, prospectively classify CLABSI 
according to the US Centers for Disease Control's 
(CDC) National Health and Safety Network criteria.9
Qadir et al10 from our NICU have reported a sustained 
reduction in multidrug-resistant bloodstream infec-
tion (BSI) by using simple evidence-based strategies, 
which included hand washing certification for all staff, 
use of chlorhexidine instead of povidone iodine for 
skin preparation, use of non-sterile gloves for diaper 
change, implementation of barrier nursing for clini-
cally suspected and culture-proven infections, provision 
of separate intubation and central line trolley for each 
room and limiting the use of umbilical catheters to 7 
days. These interventions and data are from June 2010 
to December 2011. Since then, our utilisation of central 
lines, especially peripherally inserted central catheters 
(PICC) has increased due to awareness of its utility but 
simultaneously our CLABSI rates have climbed high. Our 
NICU CLABSI rates have been around 9/1000 central 
line days over the last 5 years (2011–2015), with a line 
utilisation ratio of 0.36. Approximately 60% of our 
CLABSI are Gram-negative organisms, which are mostly 
MDR organisms (MDRO) (unpublished data).
Since 2014, we have gradually moved from 12-bedded 
facility to a 24-bedded unit to accommodate the increasing 
number of deliveries and referrals. With this increase in 
bed space, and our high CLABSI rates, it became imper-
ative to initiate a quality improvement programme to 
reduce CLABSI rates. Therefore, we intend to introduce 
an evidence-based CLABSI prevention package (CPP) 
to improve CLABSI rates in our NICU within limited 
resources.
Objectives: We intend to implement a quality improve-
ment programme by introducing evidence-based CPP 
and measure its impact on CLABSI rates.
Study design: Preanalysis and postanalysis design using 
PDCA (Plan DoCheck Act)model.
Settings: AKUH NICU.
Duration:Twelve months  (from 1 January2017 to 31 
December 2017).
Inclusion criteria
All patients admitted to AKUH NICU from 1 January 2016 
to 31 December 2017, who have central line in place.
operAtIonAl defInItIons
1. Central line: a catheter that ends at or close to heart 
or in any of the great vessels and is to be used for 
haemodynamic monitoring, infusions and blood 
sampling. The following will be considered great 
vessels: aorta, superior vena cava, inferior vena 
cava, brachiocephalic or innominate veins, internal 
jugular veins, subclavian veins, external iliac veins 
and common femoral veins. Central lines that will 
be included are PICC line, Umbilical arterial and 
venous lines and central venous line, which includes 
tunnelled and cuffed or non-tunnelled femoral lines.
2. Laboratory-confirmed bloodstream infection (LCBI): 
LCBI will be defined as:
a. A patient with a recognised pathogen cultured 
from one or more blood cultures, where the 
organism cultured was not related to an infection 
at another site; or
b. A patient found to have a common skin 
contaminant (eg, coagulase-negative 
staphylococci, viridans group streptococci 
or micrococci, diphtheroids, Bacillus sp, 
Propionibacterium sp) cultured from two or more 
blood cultures and one or more of the following 
signs or symptoms: fever >38°C, hypotension or 
hypothermia <37°C, apnoea or bradycardia and 
where signs, symptoms and positive laboratory 
results were not related to an infection at another 
site.
3. CLABSI: according to the CDC, CLABSI is defined 
as an LCBI where central line or umbilical catheter 
(UC) was in place for >2 calendar days on the date 
of the event, with day of device placement being on 
day 1, and the line was also in place on the date of the 
event or the day before. For this study, only the first 
CLABSI will be included for a particular line.
4. Device days: total number of days of exposure to de-
vice (central line) by all patients in NICU.
5. CLABSI rates: total number of CLABSI divided by the 
total number of device days 1000.
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6.  Device utilisation ratio: proportion of patients for 
which device is used, that is, number of device days/
number of patient days 100.
7. Pan-sensitive microorganisms: those organisms that 
are sensitive to all first-line antibiotics.
8. MDRO: multidrug resistance is defined as resistance 
(R) to at least one agent in three or more tested anti-
microbial categories.
9. Carbapenem resistance: it is defined as a result of 
intermediate (I) or R to imipenem or meropenem.
Methodology And dAtA collectIon
The study will be performed in three phases.
phase I: preimplimentation phase
In this phase, all patients from 1 January 2016 to 31 
December 2016, with central line in place for >2 calendar 
days, with the day of line placement as day 1, will be 
enrolled.
Patient days, device days, CLABSI rates, line utilisa-
tion ratio and hand hygiene compliance over the past 12 
months (January–December 2016) will be retrieved from 
the hospitals infection control data base.
phase II: implementation phase
In this phase, evidence-based CPP will be introduced 
from 1 January 2017 to 31 March 2017. All patients with 
central line in place for >2 calendar days, with day of line 
placement as day 1, will be enrolled and followed-up until 
either transfer from NICU to step-down unit, discharge 
or death.
phase III: follow-up phase
In this phase, all patients from 1 April 2017 to 31 December 
2017, with central line in place for >2 calendar days with 
day of device placement as day 1, will be enrolled and 
followed-up until either transfer from NICU to step-down 
unit, discharge or death.
Prospectively collected data regarding patient days, 
device days, device utilisation ratio and CLABSI rates will 
be obtained from hospital infection control surveillance 
data bases monthly and recorded on a separate excel 
sheet.
In addition, a team composed of an attending neona-
tologist, NICU infection control nurse and infection 
control team would review the patients in the NICU and 
check the CLABSI cases submitted to ensure data quality. 
All data will be collected by a NICU fellow not involved 
in the CPP.
The following data will be recorded for all patients: 
data regarding gestational age, chronological age, birth 
weight and current weight, place of birth, length of 
NICU stay, brief clinical summary along with date, time 
and reason for removal will be recorded. Dwell time 
for each line will also be recorded. Total days of paren-
teral nutrition will also be recorded. Device day at which 
CLABSI is confirmed will also be noted. Microorganisms 
will be identified and antibiotic susceptibility profiles will 
be obtained from laboratory reports and recorded on a 
predefined proforma. Susceptibility results are usually 
reported using the category interpretations of suscep-
tible, I, R or not tested. Microorganisms will be classified 
on the basis of their sensitivity patterns into pan-sensitive, 
MDRO and carbapenem-resistant organism (CRO).
CPP proforma is shown in online supplementary file.
After a literature search, the following evidence-proven 
interventions have been identified for reducing CLABSI 
rates in NICU, which will be implemented over a period 
of 3 months (Phase II):
1. Hand hygiene
a. Repeated reminders by regular hand hygiene 
week and champion of the month award11 (IA)i;
b. Non-sterile gloves for routine handling of babies 
<1000 g12 (IA)i.
2. Central line insertion
a. Hand hygiene with hospital-approved alcohol-
based product or antiseptic-containing soap 
before and after palpating insertion sites and 
before and after inserting central line13–15 (IA)i;
b. Use of maximal barrier precautions (including 
sterile gown, sterile gloves, surgical mask, hat and 
large sterile drape)13 16 (IA)i;
c. Disinfect skin with appropriate antiseptic (eg, 
2% chlorhexidine, 70% alcohol) before catheter 
insertion13 17 18 (IA)i;
d. Use either a sterile transparent semi-permeable 
dressing or sterile gauze to cover the insertion 
site19–21 (IA)i;
e. Central line insertion certification of 
physicians22–24 (IB)i;
f. Reinforcement of central line kit and 
implementation of dressing/readjustment kit25 
(IA)i;
g. Elective central line insertions at day time.
3. Central line maintenance
a. Closed medication system and two person process 
for all dressing change and tubing change26 (IB)i;
b. Perform hand hygiene with hospital-approved 
alcohol-based product or antiseptic-containing 
soap before and after accessing a catheter or 
changing the dressing13–15 (IA)i;
c. Maintain aseptic technique when changing 
intravenous tubing and when entering the 
catheter including ‘scrub the hub’20 25 27 (IA)i;
i Ranking system for evidence according to the CDC/Healthcare 
Infection Control Practice Advisory Committee System: category 
IA: strongly recommended for implementation and strongly 
supported by well-designed experimental, clinical or epidemi-
ological studies. Category IB: strongly recommended for imple-
mentation and supported by some experimental, clinical or 
epidemiological studies and a strong theoretical rational. Cate-
gory IC: required for implementation, as mandated by federal 
and/or state regulation or standard. Category II: suggested for 
implementation and supported by suggestive clinical or epide-
miological studies or a theoretical rationale or a consensus by a 
panel of experts.
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d. Evaluate the catheter insertion site daily for signs 
of infection and to assess dressing integrity. At 
a minimum, if the dressing is damp, soiled or 
loose, change it aseptically and disinfect the skin 
around the insertion site with an appropriate 
antiseptic18 20 27 28 (IB)i;
e. Daily review of catheter necessity with prompt 
removal when no longer essential13 29 (IB)i ii;
f. Minimising the access points30 (IA)i ii;
g. Heprin in TPN (0.5 Units/mL)31 (IA)i ii.
4. Organism-specific prevention (fungal infections):
a. Fluconazole prophylaxis for babies <1000 g 
(intravenous fluconazole 6 mg/kg/dose after 
every 2 days)32 (IA)i;
b. Minimise the use of H2 receptor blocker and 
proton pump inhibitor33 (II)i;
c. Minimise the use of broad-spectrum antibiotics34 
(II)i.
5. Nurse empowerment35
a. Nurse empowerment will be the cornerstone of 
the project. A dedicated infection control NICU 
nurse will be identified and empowered to take 
charge of the overall implementation of CPP.
b. Her/his responsibilities will be as follows:
i. Collect and record daily patient days, device 
days and device utilisation ratio;
ii. Collect and record all infections in NICU;
iii. Twice monthly meeting with hospitals 
infection control team to identify CLABSI 
from the BSI;
iv. Daily assessments of all central line insertion 
checklists for completeness and deficiencies;
v. Daily feedback to concerned physician and 
nurse regarding deficiencies in central line 
insertion and maintenance;
vi. Ensure hand hygiene is practised and its 
compliance is 100%;
vii. Ensure all components of evidence-based 
CPP are practised;
viii. Monthly reporting of data to NICU faculty 
and quarterly to service line chief.
outcoMes, AnAlysIs plAn, results And reportIng
Our primary outcome is CLABSI rates following imple-
mentation of our QI programme. Secondary outcomes 
may show a decrease in line utilisation ratio, improved 
hand hygiene compliances and reduction in fungal 
infections. We also intend to demonstrate microor-
ganism profiles and their antimicrobial resistance 
patterns.
Final analysis will be done on SPSS V.22.
For all three phases, descriptive analysis will be 
performed for all variables. Nominal data like age, 
ii Points d, e and f will be reviewed daily by using sticker 
(attached).
weight, gestational age, length of hospital stay, catheter 
dwell time and TPN days will be presented as mean±SD. 
Categorical data like source of admission, outcomes, 
birth weight and gestational age categories, diagnosis, 
catheter type will be presented as frequencies and 
percentages.
To compare the effect of intervention, we will use inde-
pendent sample t-test for continuous outcomes, whereas 
Χ2 test will be used for categorical outcomes. Relative risk 
ratios, 95% CIs and p values will be determined for all 
outcomes. Probability values <0.05 using two-sided tests 
will be considered significant. Incidence density will be 
calculated and Poisson regression will be used to deter-
mine factors associated with incidence of CLABSI. Micro-
biological profiles and their antimicrobial resistance 
pattern will be reported as pan sensitive, MDRO and 
CRO. We will use SQUIRE V.2.0. Guidelines for reporting 
our findings.36
dIscussIon And conclusIon
CPP is designed to improve the quality of care by reducing 
CLABSI in our unit. The project will help in identifying 
and comparing the risk factors for development of 
CLABSI and the impact of evidence-based interventions 
in reducing it. It will also help in understanding the spec-
trum of microorganisms related to the development of 
CLABSI and their antimicrobial resistance patterns.
We feel confident that we will be able to achieve this 
by meticulous implementation and monitoring of this 
programme. This research will shed light on the extent of 
this unaddressed and under-reported problem, especially 
in our part of the world and will possibly find cost-effec-
tive solutions which will lead to long-term changes in our 
NICU protocols and may be helpful for other similar 
units in low-income countries.
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